Amicus Expands into Gene Therapy with Celenex Acquisition

Amicus Therapeutics said today it has acquired Nationwide Children’s Hospital spinout Celenex for up to $452 million, in a deal that expands the rare disease drug developer into gene therapy with a portfolio of 10 clinical and preclinical programs in neurologic lysosomal storage disorders (LSDs).The 10 adeno-associated virus 9 (AAV9) gene therapy programs—developed at the hospital’s Center for Gene Therapy and The Ohio State University, both based in Columbus, OH—include